CAJ | 학술논문

目的：探讨和研究人血白蛋白治疗脑干出血的临床治疗效果和远期预后°方法选取2013年6月—2014年5月在该院治疗的脑干出血患者98例,按照随机原则分成实验组和对照组°对照组患者给予常规的药物进行治疗,实验组患者则在对照组治疗的基础上,再增加服用人血白蛋白予以治疗,在两组患者接受治疗前后,对比格拉斯哥昏迷评分(GCS﹚HE格拉斯哥预后评分(GOS)°结果在治疗的过程中,实验组患者的死亡率为14%,对照组患者的死亡率为12.5%,将两组患者的死亡率对比,差异无统计学意义(χ2=0.163,P>0.05﹚；在治疗20 d之后,除去死亡的病例,实验组患者的GCS评分为(11.31±2.12﹚分,明显高于对照组,该两组患者的GCS评分对比,差异有统计学意义(P<0.05﹚°实验组患者的GOS评分为(4.16±0.66﹚分,明显高于对照组患者,该两组患者的GOS评分对比,差异有统计学意义(P<0.01﹚°结论对于脑干出血患者,给予药物人血白蛋白进行治疗,能够有效降低格拉斯哥昏迷评分指标,提升格拉斯哥预后评分,极大地改善了患者的预后°
목적：탐토화연구인혈백단백치료뇌간출혈적림상치료효과화원기예후°방법선취2013년6월—2014년5월재해원치료적뇌간출혈환자98례,안조수궤원칙분성실험조화대조조°대조조환자급여상규적약물진행치료,실험조환자칙재대조조치료적기출상,재증가복용인혈백단백여이치료,재량조환자접수치료전후,대비격랍사가혼미평분(GCS﹚HE격랍사가예후평분(GOS)°결과재치료적과정중,실험조환자적사망솔위14%,대조조환자적사망솔위12.5%,장량조환자적사망솔대비,차이무통계학의의(χ2=0.163,P>0.05﹚；재치료20 d지후,제거사망적병례,실험조환자적GCS평분위(11.31±2.12﹚분,명현고우대조조,해량조환자적GCS평분대비,차이유통계학의의(P<0.05﹚°실험조환자적GOS평분위(4.16±0.66﹚분,명현고우대조조환자,해량조환자적GOS평분대비,차이유통계학의의(P<0.01﹚°결론대우뇌간출혈환자,급여약물인혈백단백진행치료,능구유효강저격랍사가혼미평분지표,제승격랍사가예후평분,겁대지개선료환자적예후°
Objective To explore and study the clinical therapeutic effect and long-term prognosis of human serum albumin in the treatment of brainstem hemorrhage. Methods 98 cases with brainstem hemorrhage treated in our hospital from June 2013 to May 2014 were selected and randomly divided into the experimental group and the control group. The control group were treated by the conventional drug treatment, and the experimental group were treated by human serum albumin based on the treatment given to the control group. Glasgow Coma Score (GCS) and Glasgow Outcome Scale(GOS) of the patients before and after treatment were com_pared. Results During the treatment, the mortality rate of the experimental group was 14%, and that of the control group was 12.5%, there was no significant difference in mortality rate between the two groups (χ2=0.163, P>0.05). After 20 days of treatment, except the death cases, the GCS score of the experimental group was (11.31 ±2.12) points, much higher than that of the control group, the difference in GCS score between the groups was statistically significant (P<0.05); The GOS score of the experimental group was (4.16±0.66) points, obviously higher than that of the control group, the difference in GOS score between the groups was statistically significant(P<0.01). Conclusion For patients with brain stem hemorrhage, human serum albumin can effectively reduce the Glasgow coma score and enhance the Glasgow outcome score, which greatly improves the prognosis of the patients.